https://www.selleckchem.com/pr....oducts/Temsirolimus.
In the intention-to-treat analysis for men and for women, there were no significant effects for treatment or time on MVPA. In a planned secondary analysis that considered only those adherent to EFI (completed ≥ 66% of sessions; per-protocol), bouted MVPA (ie, in sustained bouts of ≥ 10 min) was higher in women in the EFI group (mean= 132.6 ± 135.2 min/wk at 52 weeks) compared with UC (111.8 ± 113.1; P= 0.013). Regarding secondary outcomes, in women, a treatment group main effect was observed for blood pressure (P= 0.011) and exerci
Like
Comment
Share
